|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
Celgene Sees Revenue Doubling by 2017 [January 26, 2013]
Celgene Up on Psoriatic Arthritis Data [September 6, 2012]
Gilead Sciences, Biogen Idec, and Celgene [August 13, 2012]
Celgene Withdraws Revlimid Extension in Europe [June 21, 2012 Celgene press release]
2013
|
|||
 |
|
||
01/24/2013 |
04/25/2013 |
||
Q4 2012 |
Q1 2013 |
Q2 2013 |
Q3 2013 |
2012 |
|||
|
|
|
|
01/26/2012 |
4/26/2012 |
07/26/2012 |
10/25/2012 |
Q4 2011 |
Q1 2012 |
Q2 2012 |
Q3 2012 |
2011 |
|||
|
|
|
|
01/27/2011 |
04/28/2011 |
07/28/2011 |
10/27/2011 |
Q4 2010 |
Q1 2011 |
Q2 2011 |
Q3 2011 |
2010 |
|||
|
|
|
|
01/28/2010 |
04/29/2010 |
07/29/2010 |
10/28/2010 |
Q4 2009 |
Q1 2010 |
Q2 2010 |
Q3 2010 |
2009 |
|||
|
|
|
|
01/29/2009 |
04/30/2009 |
07/23/2009 |
10/22/2009 |
Q4 2008 |
Q1 2009 |
Q2 2009 |
Q3 2009 |
2008
|
|||
|
|
|
|
10/23/2008 |
07/24/2008 |
05/08/2008 |
01/31/2008 |
Q3 2008 |
Q2 2008 |
Q1 2008 |
Q4 2007 |
2007 |
|||
|
|
|
|
10/25/2007 |
07/26/2007 |
05/03/2007 |
|
Q3 2007 |
Q2 2007 |
Q1 2007 |
|
Celgene is a biotechnology company; products include Thalomid, Revlimid and Ritalin.
Celgene Short and Long Views [April 27, 2012]
Celgene Q3 shows model strength [Nobember 7, 2011]
Celgene Readies Arsenal [August 2, 2011]
Celgene (CELG) ASH Data Points [December 11, 2010]
Celgene Gathers Momentum [November 1, 2010]
Celgene Q1 Advance on Revlimid, Vidaza [May 5, 2010]
Celgene Q4 2009 Earnings and Revenue Estimates [January 11, 2010]
Celgene to Grow Rapidly [September 7, 2008]
Celgene Data for Revlimid, Vidaza, Amrubicin [June 15, 2008]
Celgene Optimism [February 4, 2008]
Celgene (CELG) and Pharmion (PHRM) [November 24, 2007 blog]
Pharmion Acquisition [November 19, 2007 press release]
Celgene in Hypergrowth [May 23, 2007 blog]
Celgene Web site:
Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but its possible. Before making or terminating an investment you should always verify any factual basis of your decision.